DCOY
NASDAQ · Biotechnology
Decoy Therapeutics Inc
$6.71
+0.41 (+6.51%)
Financial Highlights (FY 2025)
Revenue
1.28M
Net Income
141.5K
Gross Margin
55.2%
Profit Margin
11.1%
Rev Growth
+11.3%
D/E Ratio
0.31
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 55.2% | 55.2% | 55.2% |
| Operating Margin | 13.8% | 14.2% | 15.7% |
| Profit Margin | 11.1% | 8.8% | 10.6% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.28M | 1.20M | 1.36M |
| Gross Profit | 704.6K | 660.2K | 751.5K |
| Operating Income | 175.6K | 170.0K | 213.8K |
| Net Income | 141.5K | 105.1K | 144.5K |
| Gross Margin | 55.2% | 55.2% | 55.2% |
| Operating Margin | 13.8% | 14.2% | 15.7% |
| Profit Margin | 11.1% | 8.8% | 10.6% |
| Rev Growth | +11.3% | +13.4% | -9.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 437.0K | 457.4K | 468.9K |
| Total Equity | 1.41M | 1.62M | 1.55M |
| D/E Ratio | 0.31 | 0.28 | 0.30 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 291.4K | 241.4K | 275.9K |
| Free Cash Flow | 83.4K | 101.2K | 72.7K |